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S U M M A R Y
Objectives: Invasive fungal infections (IFI) are a signiﬁcant cause of morbidity and mortality in
hematopoietic stem cell transplant (HSCT) recipients. Hepatosplenic candidiasis (HSC) is deﬁned as a
distinct form of invasive candidiasis, with liver, spleen, and kidney involvement, in patients with
hematological disorders.
Methods: The charts of 255 patients (male/female 168/87; median age 35 (range 16–71) years) who
were evaluated pre-HSCT at the Gazi University Hospital Stem Cell Transplantation Unit between 2003
and 2008, were retrospectively reviewed.
Results: HSC, which was demonstrated in six (2.3%) patients, was found to be more common in
allogeneic HSCT recipients than in autologous HSCT recipients and in patients who had received two or
more previous chemotherapy courses than in patients who had received fewer than two (p > 0.05).
Patientswith HSC tended to have aworse performance status than patients without HSC according to the
World Health Organization (p = 0.001) and Karnofsky scale (p = 0.007). Pre-transplantation ferritin
(p = 0.008) and acute phase reactant levels, including erythrocyte sedimentation rate (p = 0.025) and C-
reactive protein (p = 0.007), were signiﬁcantly higher in patients with HSC than in patients without HSC.
Conclusions: This study shows the predictive role of pre-transplantation ferritin levels in selecting a
subset of patients at increased risk for HSC. Pre-transplantation risk assessment and targeted strategies
might lower the morbidity and mortality of IFI in HSCT recipients.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Invasive fungal infections (IFI) are a signiﬁcant cause of
morbidity and mortality in hematopoietic stem cell transplant
(HSCT) recipients.1 Hepatosplenic candidiasis (HSC), or chronic
disseminated candidiasis, is a serious clinicopathological entity
with predominant involvement of the liver, spleen and
occasionally kidneys by candidal microabscesses.2 The reported
frequency of HSC ranges between 3% and 29%.3–7 Anttila et al.
reported HSC in 6.8% of 562 acute leukemia patients.4 In an
autopsy series, HSC was demonstrated in 67 (9%) of 731 HSCT
recipients.6
HSC is more common in patients who receive highly mucotoxic
chemotherapeutic agents.3 The typical clinical ﬁndings of HSC are
persistent fever, abdominal pain, nausea, vomiting, and elevated
serum alkaline phosphatase levels.8 The increased frequency of* Corresponding author. Tel.: +90 312 202 63 17; fax: +90 312 223 67 14.
E-mail address: zyegin@gazi.edu.tr (Z.A. Yegin).
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doi:10.1016/j.ijid.2009.11.028HSC in immunosuppressed patients may be attributed to the
increased availability of various diagnostic procedures, such as
magnetic resonance imaging (MRI) and histopathologic examina-
tion.4 Although Candida may not be detected by blood cultures,
different organs such as liver, spleen, kidney, lung, skin, and bone
may become seeded by Candida during the neutropenic period.3,9
Candida species are the most commonly isolated fungal pathogens
in immunosuppressed patients. The accurate diagnosis of HSC is
based on tissue biopsy showing budding yeast/pseudohyphae or
positive blood cultures for Candida in the presence of radiological
evidence. The difﬁculty in early diagnosis and lack of effective
antifungal prophylaxis are claimed to be the major causes of poor
outcome.2
Iron overload (IO) has a signiﬁcant role in the pathogenesis of
various infections through free radical-induced tissue damage.
Serum ferritin levels and transferrin saturation (TS) are indicated
as predictors of body iron stores.9,10
We planned this retrospective study to determine clinical and
biological risk factors, including iron parameters, in the pathogen-
esis of HSC in HSCT candidates.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Characteristics of patients with hepatosplenic candidiasis
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age (years)/gender 33/F 24/F 25/F 33/M 52/M 29/M
Diagnosis NHL MDS HD AML AML AML
Transplant type Autologous Allogeneic – – Allogeneic Allogeneic
Conditioning regimen BEAM BuCy – – TBIFlu BuCy
GVHD prophylaxis – Cyclosporin A,
methotrexate
– – Cyclosporin A,
methotrexate
Cyclosporin A,
methotrexate
Antifungal prophylaxis Fluconazole
100 mg/day
Fluconazole
100 mg/day
– – Fluconazole
100 mg/day
Fluconazole
100 mg/day
Pre-transplant ferritin (ng/ml) 9066.1 1842.7 991.7 3485 956.6 2000
Pre-transplant ALP (U/l) 148 81 158 54 95 NA
HSC time Day 20 Pre-transplant Pre-transplant Pre-transplant Day 208 Day 20
HSC type Probable Probable Proven Probable Probable Probable
Infection site Hepatosplenic Splenorenal Hepatosplenic Hepatosplenic Hepatosplenic Hepatosplenic
Diagnostic procedure USG/CT CT Tissue biopsy CT MRI MRI
Concomitant fungal infection PFI – – PFI PFI –
Current status Dead Dead Dead Alive Alive Dead
Cause of mortality Progressive
disease
Infection Infection – – Infection
ALP, alkaline phosphatase; ; AML, acutemyelogenous leukemia; BEAM, carmustine, etoposide, cytosine arabinoside,melphalan; Bu, busulfan; CT, computerized tomography;
Cy, cyclophosphamide; F, female; Flu, ﬂudarabine; GVHD, graft-versus-host disease; HD, Hodgkin’s disease; HSC, hepatosplenic candidiasis; M, male; MDS, myelodysplastic
syndromes; MRI, magnetic resonance imaging; NHL, non-Hodgkin’s lymphoma; PFI, pulmonary fungal infection; USG, ultrasonography; TBI, total body irradiation.
Table 2
Comparison of patient pre-HSCT parameters based on hepatosplenic candidiasis
status
HSC-negative HSC-positive p-Value
Age (years) 36 (16–71) 31 (24–52) >0.05
Gender (F/M) 84/165 3/3 >0.05
Ferritin (ng/ml) 540 (2.1–7204) 1921.3 (956–9066) 0.008
TS (%) 22 (6–205) 69 (58–80) >0.05
AST (U/l) 19 (4–117) 13 (9–17) >0.05
ALT (U/l) 21.5 (4–221) 19.5 (18–21) >0.05
GGT (U/l) 27 (22–485) 31.5 (28–35) >0.05
ALP (U/l) 100 (12–367) 88 (81–95) >0.05
TPN (+/) 94/155 2/4 >0.05
ESR (mm/h) 42.9 (0–160) 95.0 (80–111) 0.025
CRP (g/l) 13.8 (0–243) 132.0 (50–252) 0.007
Albumin (g/dl) 4.5 (2.3–5.8) 3.6 (3.1–4.1) 0.022
Results are given as median (range) or n/n.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate amino-
transferase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; F, female;
GGT, gamma-glutamyl transferase; HSC, hepatosplenic candidiasis; HSCT, hema-
topoietic stem cell transplant; M, male; TPN, total parenteral nutrition; TS,
transferrin saturation.
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The charts of 255 patients (male/female 168/87; median age 35
(range 16–71) years) who were referred to the Gazi University
Hospital Stem Cell Transplantation Unit between 2003 and 2008
for HSCT, were retrospectively reviewed. Medical data including
patient characteristics, type and treatment of underlying disorder,
risk factors such as diabetes mellitus, steroid administration,
neutropenia and immunosuppressive therapy, liver function tests,
transfusion burden, and iron status were evaluated.
Proven HSCwas deﬁned as multifocal lesions in the liver and/or
spleen on imaging techniques and a speciﬁc diagnosis of fungal
infection established by the examination of deep-tissue biopsy
specimens or blood cultures. Infection was designated as probable
when multifocal lesions were shown in the liver and/or spleen by
imaging techniques in the absence of microbiological and
histopathological evidence.11 Patients who had a fungal infection
without any evidence of liver or spleen involvement were not
considered to have HSC. At least two sets of blood cultures were
obtained at the onset of fever and were repeated in cases of
persistent fever. Liver tissue was obtained by ultrasound-guided
needle biopsy from selected patients. All biopsy specimens were
subjected to culture, pathological examination, and staining.
Imaging studies including computed tomography (CT), ultrasono-
graphy, and magnetic resonance imaging (MRI) were performed
for each patient.
3. Statistical analysis
Continuous variables in two groups were compared using the
Mann–Whitney U-test. Categorical variables were compared using
the Chi-square test. A p-value of<0.05was accepted as statistically
signiﬁcant. The calculations were carried out using SPSS 11.5 (SPSS
Inc., Chicago, IL, USA).
4. Results
HSCwas demonstrated in six (2.3%) of 255 patients in our study
cohort. Five patients had probable and one patient had provenHSC.
HSC was more common in allogeneic HSCT recipients than
autologous HSCT recipients and in patients who had received
two or more previous chemotherapy courses than in patients who
had received fewer than two (p > 0.05). Patients with HSC tendedto have a worse pre-HSCT performance status (PS) than patients
without HSC according to the World Health Organization
(p = 0.001) and Karnofsky scale (p = 0.007). Patient characteristics
are summarized in Table 1.
Pre-transplantation ferritin levels were signiﬁcantly higher in
patients with HSC than in patients without HSC (1921.3 (956–
9066) ng/ml vs. 540 (2.1–7204) ng/ml; p = 0.008). Pre-transplanta-
tion TS levels were found to be higher in patients with HSC than in
patients without HSC (69% (58–80) vs. 22% (6–205)), without
statistical signiﬁcance (p > 0.05). Pre-transplantation acute phase
reactants, including erythrocyte sedimentation rate (95.0 (80–111)
mm/h vs. 42.9 (0–160) mm/h; p = 0.025) and C-reactive protein
(132.0 (50–252) g/l vs. 13.8 (0–243) g/l; p = 0.007), were
signiﬁcantly higher, while albumin levels were lower (3.6 (3.1–
4.1) g/dl vs. 4.5 (2.3–5.8) g/dl; p = 0.022), in patients with HSC
when compared to patients without HSC. Pre-transplantation data
categorized according to HSC status are shown in Table 2.
The overall mortality rate was found to be 66.7% in the HSC
group. The cause of mortality was progressive disease in one
patient and infection in three patients. Univariate andmultivariate
analysis could not be performed due to the small number of
patients with HSC.
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Infections are one of the major causes of morbidity and
mortality in patients with hematological malignancies. IFI has
become a signiﬁcant problem in this group of patients with the
emergence of more intensive cytotoxic regimens. HSC is a distinct
form of IFI, which is extremely difﬁcult to diagnose and manage.
Blood cultures are positive in less than 50% of patients and biopsy
may not be sufﬁcient to demonstrate the fungal infection.
Moreover, persistent neutropenia may mask the lesions and HSC
might become invisible on imaging studies, such as CT scans.2,3,8,12
HSC was demonstrated in six (2.3%) patients in our study
cohort. Although data concerningHSC in patients undergoingHSCT
are limited, the incidence appears to have increased over time. The
reported frequency of HSC ranges between 3% and 29%.3,4,6,8
Autopsy ﬁndings have demonstrated a high HSC incidence in acute
leukemia (3.8–6.8%) and in HSCT recipients (9%), as expected.8
HSC was more common in allogeneic HSCT recipients than
autologous HSCT recipients and in patients who had received two
or more chemotherapy courses prior to HSCT than in patients who
had received fewer than two. Several predisposing factors have
previously been described for HSC, including vascular devices,
parenteral nutrition, mucositis, and intensive chemotherapy.
Furthermore, younger age, prolonged neutropenia, and prophy-
lactic use of quinolone antibiotics have been reported as
independent risk factors for the development of HSC in patients
with acute leukemia.2,3 It has also been indicated that patients
with GVHD have a tendency to acquire opportunistic infections,
presumably due to the underlying T-cell defects or immunosup-
pressive treatment.5,13 Poor PS has been considered to be an
important prognostic factor for candidemia in cancer patients.14
Similarly, the pre-HSCT PS of our patientswithHSCwas found to be
worse than in patients without HSC.
Pre-transplantation serum ferritin levels were signiﬁcantly
higher in patients with HSC compared to patients without HSC,
with increased levels of pre-HSCT acute phase reactants as well,
indicating the presence of an inﬂammatory response. Ferritin,
being an iron storage protein, has a critical role in iron
homeostasis. It is currently the most used predictor of IO, as it
is cost-effective and widely available. However, it is well known
that ferritin may not be an accurate measure of total body iron
burden in patients who have ongoing acute infectious or
inﬂammatory conditions.15–18
Microorganisms require iron to survive, as iron is essential for
microbial proliferation. It is postulated that excessive iron
adversely affects the antimicrobial functions of neutrophils,
monocytes, macrophages and natural killer cells, as well as
immunoglobulin secretion and complement system function. It
is therefore considered to be a risk factor for infections with
various pathogens, including Yersinia enterocolitica, Listeria
monocytogenes, Pseudomonas, Staphylococcus, Mucorales , Vibrio
vulniﬁcus, Plasmodium falciparum, Mycobacterium tuberculosis,
Mycobacterium avium complex, Candida albicans and Aspergillus
species.1,9,10,13,15,19–26 Furthermore, based on the increased
susceptibility to fungal infections in iron-overloaded states, iron
chelation alone or combined with antifungal drugs are recom-
mended for the prevention and treatment of fungal infections
due to the antifungal effects of iron chelators.27
IO is a serious complication of HSCT and hematological
malignancies.16,23,28,29 Although iron is a critical element for cell
growth, it may be potentially toxic to the host. In a state of iron
excess, free iron acts as a free radical catalyzer, resulting in the
formation of reactive oxygen species, which promotes the
development of several complications. Iron increases the risk of
infections, sinusoidal obstruction syndrome, hepatic dysfunction,
mucositis, and idiopathic pneumonia syndrome in HSCT recipi-ents.10,16,20,30,31 IFIs in patients with IO have been reviewed
extensively in 711 thalassemia patients who underwent HSCT,
highlighting the role of transfusion burden and secondary
hemochromatosis in infectious morbidity and mortality.32 Iron-
generated tissue damage is established to be partly mediated by
non-transferrin bound iron (NTBI), indicating its more reliable
predictive value in IO when compared to ferritin.18,33–35 IO could
be a signiﬁcant contributor to treatment-relatedmortality in HSCT
recipients.10,16,28
A history of previous IFI is a challenge for HSCT candidates,
though not a contraindication.36 Although prior HSC in patients
with acute leukemia may not be an absolute contraindication for
HSCT, a prophylactic antifungal approach is generally recom-
mended.2,8 The higher morbidity and mortality rates in patients
with HSC and the enormous impact on the costs of HSCT, compell
us to determine the subset of patients who are at high risk of
developing HSC during the course of HSCT. It should be noted that
serum ferritin is a sensitive but not a speciﬁc marker for IO and
may be a poor predictor of excess tissue iron, particularly in the
presence of infection and inﬂammation. The etiology of the
elevated ferritin levels in our patients with HSC remains to be
clariﬁed. Although elevated ferritin levels appear to be a part of the
acute phase reaction in our series, the inﬂammatory milieu of the
patients may have masked a coexistent IO. The higher transferrin
saturation ratio, though without statistical signiﬁcance, suggests a
possible role of IO. NTBI might be a more sensitive marker in
predicting the role of IO in IFI. One other possibility is that the
inﬂammatory response in the group of patients with HSC prior to
transplantation might have been a sign of an occult systemic
Candida infection, which presented with overt clinical signs with
the recovery of neutrophils and immune functions after trans-
plantation.
No matter the cause, high serum ferritin levels appear to
deﬁne a subset of patients at increased risk of HSC. Whether the
inﬂammatory state or IO, or a combination of these two, is the
cause of hyperferritinemia remains to be elucidated. Pre-
transplantation risk assessment and risk adapted strategies
might lower the morbidity and mortality of IFI in HSCT
recipients.
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